WebHe recently announced his retirement from iRhythm’s Board of Directors. Before joining iRhythm, Mr. King was President, Chief Executive Officer and Director of Affymetrix, Inc. (now part of Thermo Fisher Scientific), a previously publicly-traded technology innovator in the field of genetic analysis, where he spent four years. WebOct 13, 2024 · SAN FRANCISCO, Oct. 12, 2024 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC) (“iRhythm”), a leading digital healthcare solutions …

GOVERNANCE Galderma

Web• Founding Investor, Chair/Member, Board of Directors iRhythm - NASDAQ:IRTC (wearable cardiovascular devices), ... Mike is a Board Director at DNAnexus, Scipher Medicine, Sherlock Biosciences, SpeeDx, and Teckro. Previously, Mike was the Co-founder and Managing Partner of Sands Capital Ventures, a global cross-industry venture capital ... WebDaniel Wilson has served as iRhythm’s Executive Vice President of Strategy, Corporate Development and Investor Relations since June 2024. Previously, he served as Director … inconsistency\\u0027s 9d

iRhythm® Technologies Announces Kevin King to Retire from Board …

WebMar 14, 2024 · SAN FRANCISCO, March 14, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC) (“iRhythm”), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that Kevin King will retire from iRhythm’s Board of Directors effective April 1, 2024. WebiRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data … WebAs a member of Board of Directors at IRHYTHM TECHNOLOGIES INC, Bruce G. Bodaken made $205,326 in total compensation. Of this total $60,836 was received as fees earned or paid in cash, $0 was received as non-stock incentive plan compensation, $0 was received as change in pension value and nonqualified deferred compensation earnings, $0 was … inconsistency\\u0027s 9g